



OPEN

Towards water-soluble [60] fullerenes for the delivery of siRNA in a prostate cancer model

Julia Korzuch^{1,6}, Monika Rak^{2,6}, Katarzyna Balin³, Maciej Zubko^{4,5}, Olga Głowacka², Mateusz Dulski⁴, Robert Musioł¹, Zbigniew Madeja² & Maciej Serda^{1✉}

This paper presents two water-soluble fullerene nanomaterials (HexakisaminoC₆₀ and monoglucosamineC₆₀, which is called here JK39) that were developed and synthesized as non-viral siRNA transfection nanosystems. The developed two-step Bingel–Hirsch reaction enables the chemical modification of the fullerene scaffold with the desired bioactive fragments such as D-glucosamine while keeping the crucial positive charged ethylenediamine based malonate. The ESI–MS and ¹³C-NMR analyses of JK39 confirmed its high T_h symmetry, while X-ray photoelectron spectroscopy revealed the presence of nitrogen and oxygen-containing C–O or C–N bonds. The efficiency of both fullerenes as siRNA vehicles was tested in vitro using the prostate cancer cell line DU145 expressing the GFP protein. The HexakisaminoC₆₀ fullerene was an efficient siRNA transfection agent, and decreased the GFP fluorescence signal significantly in the DU145 cells. Surprisingly, the glycofullerene JK39 was inactive in the transfection experiments, probably due to its high zeta potential and the formation of an extremely stable complex with siRNA.

Nanotechnology has changed traditional medicinal chemistry, by enabling the development of small molecular drugs with targeted nanotherapeutics¹. The central premise of medical chemistry is that a specific small molecule can bind to the desired enzyme or receptor, which results in a specific therapeutic effect. The aforementioned inhibition process can also be achieved using nucleic acid therapies including a technique called RNA interference (Nobel Prize 2006) in the presence of engineered nanomaterials used as transfection agents^{2,3}. An efficient transfection agent must deliver the targeted siRNA into the cytoplasm where it degrades the targeted mRNA after binding to the argonaute proteins (AGO) and the further formation of the RNA-induced silencing complex (RISC)⁴. Recently, the FDA has approved an siRNA-based drug (lipid nanoparticles, patisiran) to treat transthyretin-mediated amyloidosis⁵. Due to increased interest in the nanomedical approaches in molecular biology, the interactions of nucleic acids and carbon nanomaterials have been thoroughly studied and discussed, mainly focusing on the interactions of the DNA-carbon nanotubes/cationic fullerenes^{6,7}. The use of [60]fullerene hexakisadducts as DNA transfection agents was previously described in case of multivalent cationic fullerenes and polycationic fullerenes, which formed a stable complexes with DNA plasmids with minimal cytotoxicity in mammalian cells^{8–10}. Although the interaction of the cationic fullerenes with DNA is well presented even in murine models, the siRNA transfection techniques have mainly been developed for only one derivative, TPFE (*tetra*-piperazino-[60]fullerene epoxide)¹¹, which forms a stable 7 nm micelle, but has limited options for its further chemical functionalization or the addition of targeting groups or ligands for biorthogonal/click chemistry. Furthermore, the main advantages of fullerene-based transfection agents over cationic lipids are the high water-solubility, the ability to cross biological membranes, low cytotoxicity and a high synthetic accessibility allowing additional options for bioconjugation with desired drugs in engineered nanomaterials. Moreover, it has been proven that TPFE is non-toxic and is effective for lung-targeted in vivo siRNA delivery, which is based on the formation of the micrometer-sized TPFE–siRNA–serum protein complexes, which could be a stabilization factor for relatively unstable siRNA under physiological conditions¹². Studies performed by Wang et al. described a fullerene-ethylenediamine modified dextran hybrid (C₆₀-Dex-NH₂) as an efficient siRNA transfection agent when they evaluated it in the human breast cancer cell line MDA-MB-231, which could be photo-activated and could

¹Institute of Chemistry, University of Silesia in Katowice, 40-006 Katowice, Poland. ²Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland. ³Institute of Physics and Silesian Center for Education and Interdisciplinary Research, University of Silesia in Katowice, 41-500 Chorzów, Poland. ⁴Institute of Materials Engineering, University of Silesia in Katowice, 41-500 Chorzów, Poland. ⁵Department of Physics, Faculty of Science, University of Hradec Králové, 500-03 Hradec Králové, Czech Republic. ⁶These authors contributed equally: Julia Korzuch and Monika Rak. ✉email: maciej.serda@us.edu.pl

destroy the endo-lysosomal membranes via a controllable generation of ROS¹³. Simultaneously, the interactions of carbon nanomaterials with biological fluids are crucial factors that determine their cellular fate and further tissue targeting^{14,15}. Experimental and computational studies have been performed to describe the formation of complexes between the water-soluble carboxylated fullerenes and serum albumins and other proteins such as lysosome and the serine proteinases^{16,17}. Our previous studies showed that the protein corona is formed on the surface of glycofullerenes and modulates their inhibitory activity, however its detailed composition is still unknown¹⁸. Due to nanoparticle zeta-potentials influence on the formation and composition of the protein corona, it was observed that in positively charged nanoparticles after their complexation with the plasma proteins, the complex's final zeta potential decreases¹⁹.

Herein a facile methodology for the synthesis of highly water-soluble [60]fullerene hexakisadducts is presented using the Bingel-Hirsch synthetic approach to modify the buckyball scaffold. Our robust protocol was used to create two highly functionalized T_h symmetrical fullerene nanomaterials including monoglucosamine C_{60} which is called here a JK39 compound with a D-glucosamine's fragment. The rationale behind this approach was to increase the interactions of the nucleic acids with a sugar fragment as has been described for the chitosan-based transfection agents²⁰. The additional advantage of fullerene hexakisadducts is that they limit the occurrence of several regioisomers, simplify of the purification process and increase water-solubility in contrast to the fullerene monoadducts, which is particularly useful in biological experiments^{21,22}. During the designing step, we kept in mind that the glycofullerenes that we previously reported on, could localize in the nuclear envelope- which could be a beneficial property for the transfection process²³. We previously described Hexakisamino C_{60} as being a non-toxic photosensitizer that could be used to generate reactive oxygen species as described for the treatment non-melanoma skin cancer²⁴. The engineered water-soluble aminofullerenes Hexakisamino C_{60} and JK39 were designed as dual-acting nanotherapeutics, which degrade a targeted mRNA in a sequence-specific manner that might have a potential additional photodynamic activity. Considering the interactions of fullerenes with serum albumins, the transfection experiments were conducted in a FBS-containing medium to test the ability of the synthesized carbon nanomaterials to transfect the desired siRNA. We selected Lipofectamine 3000 because it is a modern transfection agent that is commonly used in molecular biological experiments²⁵.

Methods

Materials. All of the compounds that were used reagent grade or better, and the solvents were used as they were received unless otherwise specified. The following reagents were used as received: C_{60} (99.5 + %, SES Research, U.S.A.), D-glucosamine hydrochloride (Sigma Aldrich), DBU (1,8-diaza-bicyclo[5.4.0]undec-7-ene, Sigma Aldrich), ethyl hydrogen malonate (Sigma Aldrich), CBr_4 (Sigma Aldrich) and DIC. The following reagents: acetic anhydride (Fisher), pyridine (Sigma Aldrich), and DMF (Sigma Aldrich) were prepared according to the procedures in the literature, distilling them with calcium hydride and were then used immediately. The Lipofectamine 3000, which was used as the control siRNA transfection agent, was obtained from Thermo Fisher Scientific (U.S.A.). For the in vitro experiments we have used the human prostate cancer (DU145) cell line (American Type Culture Collection, Rockville, U.S.A.), 24-well plates (Corning; Falcon), a DMEM F12 Ham medium (Sigma-Aldrich, St.Louis, MO, USA), fetal bovine serum (FBS; Gibco), Penicillin–Streptomycin (Sigma-Aldrich, St.Louis, MO, USA), PTAI-11 (trimethyl undecaprenyl ammonium iodide; Collection of Polyprenols, Institute of Biochemistry and Biophysics PAS, Warsaw, Poland; PTAI-11 is patented (No. 231158, Polish Patent Office 2019; No. 230096, Polish Patent Office 2018, No. 211824, Polish Patent Office 2012) and there is a patent application pending (No. PCT/PL2015/000093, WO/2016/032348, Polish Patent Office, European Patent Office), DOPE (1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine; Sigma-Aldrich, St.Louis, MO, USA), DC-cholesterol (3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride; Sigma-Aldrich, St.Louis, MO, USA).

The nuclear magnetic resonance spectra were measured on a *Bruker Avance III 500 MHz NMR Spectrometer* with TMS as the internal standard. The MS spectra were collected using an electrospray ionization time-of-flight (ESI-microTOF) mass spectrometer from Bruker Daltonics Inc (U.S.A.). The high-resolution mass spectrometry was carried out on the ESI-Q-TOF maXis impact (Bruker Daltonics Inc, U.S.A.). The purity of all the compounds was assessed using an Agilent1260 HPLC equipped with a DAAD detector at 260 nm, RP-column: Eclipse plus C_{18} (3.5 μ m); flow 0.5 mL/min. The Fourier transform infrared (FTIR) measurements were taken using an Agilent Cary 640 FTIR spectrometer, that was equipped with a common source and a DTGS Peltier-cooled detector. The fullerene powders were measured using ATR diamond accessory in the 400–4000 cm^{-1} range. The spectrum was recorded at 32 accumulations and at a spectral resolution of 4 cm^{-1} . The dynamic light scattering and zeta potentials for the fullerene nanomaterials and their complexes with siRNA were measured using Zetasizer Nano (Malvern Panalytical Ltd, UK). The transmission electron microscopy (TEM) observations were performed using a JEOL high resolution (HR-TEM) JEM 3010 microscope operating at a 300 kV accelerating voltage, that was equipped with a Gatan 2 k \times 2 k Orius™ 833SC200D CCD camera. The chemical analysis of the surface of fullerenes was performed using the X-ray photoelectron spectroscopy (XPS) technique. The X-ray Photoelectron Spectroscopy measurements were taken using a Physical Electronic XPS spectrometer (Physical Electronics PHI 5700, Chanhassen, MN, U.S.A.). Monochromatic Al K α radiation (1486 eV) was used to excite the photoelectrons from the surface of fullerenes. The photoemission spectra were collected in a wide binding energy range (–2 to 1400 eV) and in the characteristic photoemission lines binding energy ranges of carbon, oxygen, nitrogen, and fluorine which was detected on samples' surface. The analysis was carried out using PHI MultiPak (v.9.6.0.1, ULVAC PHI, Chigasaki, Japan) software. The EGFP silencing efficiency was evaluated with an OLYMPUS IX81 (Olympus) fluorescence microscope and a Guava® easyCyte 8 flow cytometer (Luminex, Austin, TX, USA), at a 488 nm laser excitation. The percentage of GFP-positive cells was analyzed using InCyte software ver. 3.3 (Luminex, Austin, TX, USA).

Synthesis of fullerene JK39 and malonic acid ligands for Bingel–Hirsch reaction. Our group previously described the HexakisaminoC₆₀ synthetic protocol²⁴. The robust approach for obtaining fullerene nanomaterial JK39 is depicted in Scheme S1 in the Supporting Information, and includes additional spectroscopic data. The synthesis of the [60]fullerene monoadduct (5), as well as its malonic acid precursor that contains the D-Glucosamine unit (4), were also previously described by our group²³.

Ethylenediamine (15 mL; 0.25 mol) was dissolved in chloroform and cooled to 0 °C followed by the dropwise addition of 125 mL of a chloroform solution of di-*tert*-butyl bicarbonate (5.46 g; 0.025 mol) over three hours. Then, the reaction mixture was allowed to reach room temperature after which it was stirred for an additional 16 h. After that time, the solution was washed six times, with 200 mL of DI water and four times with 200 mL of brine. The organic phases were dried over MgSO₄ and evaporated under reduced pressure. The final product was obtained as a colorless oil of *N*-Boc-protected ethylenediamine (1) with a 45% yield. The *N*-Boc-1,2-diaminoethane (1 g; 6.2 mmol) was dissolved in 50 mL of methanol, and then dimethylmalonate (0.39 g; 2.95 mmol) was added dropwise. The reaction mixture was refluxed for three hours and then stirred for an additional 72 h at room temperature. After that time, the methanol was evaporated in vacuo. The final product was purified by the initial extraction (DCM/H₂O) followed by column chromatography (DCM:MeOH, 20:1). The final product (2) was obtained as a sticky off-white gum with 13% yield.

The glycofullerene monoadduct (5) (45.2 mg; 0.0365 mmol) was dissolved in 10 mL of dichloromethane and 100 mL of toluene. The mixture was stirring for 15 min. Then the *N*-Boc-diethylamine malonate (142 mg; 0.365 mmol) and CBr₄ (241.6 mg; 0.73 mmol) were dissolved in 10 mL of DCM that had been added to the fullerene solution. In the next step, DBU (66.7 mg; 0.438 mmol) was dissolved in 3 mL of dichloromethane, and 0.5 mL of the base was added to the solution for six hours. After all of the DBU was added, the reaction mixture was stirred at room temperature, for an additional 48 h, during which the color of the solution changed from red-brown to orange. The product was purified using a flash column in the gradient conditions (DCM, DCM: MeOH 10:1 to 5:1). The C₆₀ hexakisadduct (6) structure which had a T_h symmetry was confirmed using ¹³C-NMR spectroscopy and mass spectrometry. To obtain a water-soluble fullerene derivative (7), the hexakisadduct was dissolved in 10 mL of DCM, and 20% trifluoroacetic acid was added. The reaction was stirred at room temperature for 10 days, during which two phases appeared in the solution. The water phase was collected, evaporated in vacuo and purified on centrifugal membranes using a 1 kDa filter membrane (Pall Corporation, U.S.A.). The top layer of the membrane was washed five times, with 15 mL of distilled water. Subsequently, the [60]fullerene nanomaterial was frozen at –20 °C and freeze-dried. The final product was obtained as a brown solid with a 30% yield and was stored in a laboratory freezer at –20 °C. The hexakisadduct (7) was characterized using NMR spectroscopy and infrared spectroscopy, and the structure was confirmed using ESI mass spectrometry.

Imaging the siRNA-aminofullerene complexes using transmission electron microscopy. The TEM measurements that are presented in Figs. 3A,B and S8 were obtained using a JEOL high resolution (HR-TEM) JEM 3010 microscope operating at a 300 kV accelerating voltage. The samples of the fullerene–siRNA complexes (20 µL of a desired solutions in nuclease free water, R = 70; 0.45 µg siRNA GFP and 37.5 µg of fullerene nanomaterial) were deposited on a copper grid with a holey carbon amorphous film under air and then dried at room temperature for 24 h.

siRNA transfection using the fullerene nanomaterials. The human prostate cancer (DU145) cell line was obtained from the American Type Culture Collection (Rockville, U.S.A.), nr HTB-81. The DU145 cells were seeded into the wells of a 24-well plate at a density of 5 × 10⁴ and cultivated for 24 h in a DMEM F12 Ham medium with 10% FBS without antibiotics. The [60]fullerene nanomaterials and siRNA were suspended in nuclease-free water at pH 7. Next, they were mixed at a 1:1 (v:v) ratio and incubated for 30 min at room temperature. After incubation, the mixture was added to the wells with the cells that contained the FBS-supplemented medium (final FBS concentration—5%). A 0.45 µg/well of siRNA GFP (Sigma Aldrich) was used with 37.5 µg of HexakisaminoC₆₀, 37.5 µg of JK39, or 1.5 µL of Lipofectamine[®] 3000. After five hour incubation 300 µL of the medium that had been supplemented with 20% of FBS and antibiotics (Penicillin–Streptomycin [200U–0.2 mg/mL]). The mixture of PTAI-11 (trimethylundekaprenylammonium iodide; Collection of Polyprenols, Institute of Biochemistry and Biophysics PAS, Warsaw, Poland) + DOPE (1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine; Sigma Aldrich) + DC-cholesterol (3β-[*N*-(*N*′,*N*′-dimethylaminoethane)-carbonyl]cholesterol hydrochloride; Sigma Aldrich) at a 1:1:1 molar ratio in 3 µg of lipids was used 24 h after the siRNA had been introduced into the transfected cells with 2.7 µg of pEGFP-C1 plasmid as was previously described^{26,27}. To summarize, the experimental steps were: day 1—plating cells; day 2—transfection with siRNA using fullerenes or Lipofectamine[®] 3000; day 3—transfection with the pEGFP-C1 plasmid using PTAI-11 + DOPE + DC-cholesterol and day 4—evaluating the efficiency of EGFP silencing.

Results and discussion

The procedure for synthesizing HexakisaminoC₆₀ as well as its biophysical properties were published earlier, when investigating its photodynamic activity in the non-melanoma skin cancer model²⁴. The fullerene nanomaterial JK39 was obtained in a time-controlled two-step Bingel–Hirsch reaction (for the synthetic protocol, see the Supporting Information Scheme S1), in which a peracylated D-glucosamine fullerene monoadduct (5) was further modified in a second Bingel–Hirsch reaction with Boc-protected malonate (2) its high-resolution ESI spectrum is presented in Fig. S4. In general, the Boc protection on aminomalonate was more useful in the Bingel–Hirsch reaction in terms of the general yields and purification procedure than a previously used trityl function. As a result, T_h-symmetrical hexakisadduct (6) was created, whose structure was confirmed by the presence of two fullerene sp² signals at δ = 146 and 141 ppm along with an sp³ signal at δ = 69 ppm in the ¹³C-NMR spectrum of

(6) (Fig. S2). Additionally, one could also observe three characteristic signals for different types of NH groups, which are presented between 8.20 and 7.30 ppm in $^1\text{H-NMR}$ spectrum (Fig. S1) of fullerene nanomaterial (6). After the hydrolysis of [60]fullerene derivative (6) a highly water-soluble fullerene nanomaterial (7) was created, and its structure was studied using $^{13}\text{C-NMR}$ spectroscopy. The strongest signals in $^{13}\text{C-NMR}$ of fullerene nanomaterial (7) are those connected with TFA counter anion signals (both quartets are located around 162 and 115 ppm, Fig. S3) as well as the methylene groups in ethylenediamine fragments ($\text{NH-CH}_2\text{CH}_2\text{NH}$), located at 38 and 37 ppm, which are depicted in Fig. S3. Due to the limits of our ESI-MS detector (3000 Da), we were not able to measure the molecular peak of the protected fullerene nanomaterial (6) which had a molecular mass at 3109 Da; however, it was possible to detect signals from its fragmentation (Fig. S5). The peak at 2685 Da resulted from the fragmentation of *D*-glucosamine malonate ($M=459$ Da) from the parent structure with the addition of two water molecules. In contrast, the peak at 2297 Da corresponded to the fragmental structure without an acetylated *D*-glucosamine malonate unit, and one Boc-protected aminomalonate ($M=388$ Da), which was presented as an adduct with two water molecules. In the next step in our synthetic protocol, the acetyl and Boc protection were removed from the fullerene nanomaterial (6) via a TFA hydrolysis, which was followed by further membrane dialysis, to form the final water-soluble JK39, which was further characterized using the NMR, FTIR, and XPS techniques with additional measurements of its size (DLS) and zeta potential.

The ESI-mass spectrum of a water-soluble fullerene is depicted in Fig. 2B. We were not able to directly detect its molecular peak ($M=1941$ Da) due to its polycationic nature, although the spectrum did show a huge signal at 1038 Da, which corresponded to the double-charged cationic form of fullerene (7) $[\text{M}+3\text{Na}]^{2+}$.

The analysis of the infrared spectrum of JK39 is very similar to previously published Hexakisamino C_{60} and should be performed by considering two spectral regions, firstly (1) 2250–3800 cm^{-1} and secondly, (2) 400–1900 cm^{-1} (Fig. 2A)²⁴. According to this division, for both compounds region 1 is determined by the presence of the overlapping signals that had originated from the symmetric and asymmetric stretching modes of $\nu(\text{CH}_x)$, and the ammonium cations containing $\nu(-\text{CH}_2\text{NH}_x^+)$ ($x=2, 3$)²⁸. As a result of the introduction of the *D*-glucosamine fragment, an additional band at 3246 cm^{-1} can be explained by the presence of amine $\nu(\text{NH})$, and it is worth noting that its position is linked to the presence of intra- or intermolecular interactions with hydroxyl groups²⁹. It is also interesting that the character of the band arrangement within region 1 in both compounds indicated a considerable distribution and high number of *H*-bonds with different donor–acceptor bond lengths. Unfortunately, it was not easy to interpret and analyze the signal of the hydroxyl groups due to the high complexity of the spectrum, e.g. there was an increase in the intensity of the signal of JK39 above 3300 cm^{-1} , which may indicate the presence of the hydroxyl groups as a result of the introduction of the glucosamine fragment. In turn, interpreting of the bands from region 2 was much more complicated due to the higher complexity of the molecular vibration. However, two bands at around 1665 cm^{-1} and 1527 cm^{-1} referred to the asymmetric and symmetric deformation vibration of ammonium cation, while the shoulders that were observed close to those two maxima but that were located at lower wavenumbers, are related to the vibration of the ammonium cation. The literature and previously reported data for Hexakisamino C_{60} that suggested that the position of the band at 1665 cm^{-1} might also be explained by taking into account the stretching vibration of carbonyl modes due to the occurrence of the β -diketone structure^{24,30}, or due to the high dynamicity of the system through the formation of hydrogen bonds which shifted the carbonyl band maximum into lower wavenumbers. In turn, the presence of a less intense band around 1800 cm^{-1} might be explained through the presence of *N*-protonated amide moiety, which is unusual due to well-known favorable *O*-protonation process. However, it was previously discussed in the literature that some amides and peptides are *N*-protonated, especially in case of strained amides, but also for peptides with electron donating groups and α -effects^{31–33}. Other bands at the maxima around 1430, 1180, and 1120 cm^{-1} might respectively be linked to the deformational modes of the ethylenediamine groups, the rocking vibration of the ammonium cation or the skeletal vibration of the alkane chain and deformational modes of the methylene groups. The presence of sugar-based malonate was also reflected in the occurrence of low intense bands at 1369, 1285, and 1039 cm^{-1} due to the C–O–C vibration within the pyranose ring and the deformational modes of $-\text{CH}_2\text{CH}_2$ chain.

The local environment detected on the fullerene surface elements was examined using the XPS technique. Based on the analysis of the XPS survey spectra, several elements were detected on the surface of both fullerene nanomaterials. The chemical composition and calculated atomic and weight concentrations are combined for both fullerenes in Table S1 (see Supporting Information). Elements with an atomic concentration below one atomic percentage, such as Si, S, Na, Cl, and Br can be treated as contaminants. An analysis of the main components of the examined samples (C, O, N, F) indicated some variations in the atomic concentration and, consequently, in the relative ratio of the individual components. The most pronounced differences are presented in the amount of the detected carbon and nitrogen as both of the fullerene nanomaterials have the same ethylenediamine core with the main difference in the *D*-glucosamine unit (Fig. 1). The chemical state for carbon, oxygen, nitrogen, and fluorine was determined by analyzing the high-resolution spectra of the C1s, O1s, F1s, and N1s photoemission lines. It was revealed that for a particular element, the presence of several different chemical states was related to the specific chemical bonding with the surrounding elements. The analysis of the main component of the both samples—carbon indicated that carbon existed in several different chemical states (see deconvoluted C1s line in Fig. 2C). The chemical state with the lowest binding energy (282.42 eV for sample JK39 and 282.58 eV for the Hexakisamino C_{60}) was related to the occurrence of silicone contamination. The most pronounced peak in the spectra of both samples was located at 284.82 eV and was related to the presence of C–H or C–C bonds³⁴. Interestingly, oxygen and nitrogen containing groups C–O or C–N (at 287.10 eV) were detected for both samples^{35,36}, whereas the presence of typical carbonyl group (C=O) (288.18 eV) was only detected for fullerene JK39^{37,38}. For the Hexakisamino C_{60} fullerene, the peak at 288.5 eV was assigned to the O=C–OH bond, which could be also correlated to the presence of CF_3COO^- counterion³⁸. The C–F (286.3 for JK39, and 286.6 eV for Hexakisamino C_{60}) bond and $-\text{CF}_3$ fragment of trifluoroacetic acid (687.8 eV for JK39 and 687.9 eV for




Figure 1. The non-viral cationic fullerene nanomaterials Hexakisamino_C₆₀ and JK39 that were used for the siRNA transfection.

Hexakisamino_C₆₀ were identified through the F1s deconvolution presented in Fig. S9³⁹. The O1s line (Supporting Information, Fig. S9) that indicated a carbon–oxygen bond; weakly adsorbed oxygen (O₂/OH⁻) were detected at ~ 530.3 eV, C=O (carbonyl slightly below 532 eV), and O–C=O at around 533.3 eV^{40,41}. The deconvoluted N1s line (see Fig. 2C) indicated the presence of four components; the most pronounced component at 399.6 eV was assigned to the C–N³⁶ or N–(C=O)– bonds⁴², the one at 398.0 eV to basic nitrogen (pyridinic type), and the chemical state at 401.4 eV to quaternary N⁴³. Assuming that some of the nitrogen in the 398 eV bonding energy state could come from N-protonated amide fragment, the increased amount that was observed for sample JK39 (see the green line in Fig. 2C, for sample JK39, it was 22% of all of the nitrogen, for Hexakisamino_C₆₀—13%) could confirm the structure of sample JK39 with nitrogen attached to pyranose ring. We also calculated pK_a values of all nitrogen atoms in our malonate substrates which are depicted in Fig. S10. In case of D-glucosamine containing malonate pK_a of the nitrogen is 19.3, while the ethylenediamine-based malonate has to pK_a one for amine (10.2) and amide 19.5.

Based on our previous studies with water-soluble fullerenes and kinetic experiments on fullerene C₆₀ser that were conducted Wilson's group, we postulated that the synthesized fullerene nanomaterials would form smaller and larger aggregates in a water solution, that are in constant equilibrium^{18,44}. They can disaggregate when they are exposed to a higher ionic strength (salt addition), organic solvents, and the adsorption of the protein corona on the surface of fullerene¹⁸. At a concentration of 0.1 mg/mL, Hexakisamino_C₆₀ forms aggregated at 100 nm (PDI=0.2) with a zeta potential at + 28.6 mV²⁴, while the fullerene derivative JK39 formed two subpopulations of aggregates at 134 and 599 nm (PDI = 0.365) also with two different values of the zeta potential at + 54 and + 90 mV (Figs. S6, S7, Supporting Information). The presence of two signals in the zeta potential measurement of JK39 might be caused by the considerable polydispersity of the fullerene nanomaterial and could confirm its lower stability. Additionally, the studies performed by Deryabin et al. on ten different fullerene derivatives demonstrated an obvious relationship between the zeta potentials of the functionalized [60]fullerene aggregates and their size in salt-free aqueous⁴⁵. Besides, nanoparticles with a positive zeta potential have a long-circulating half-life due to the absorption of the protein corona and can form electrostatic complexes with RNA which is crucial when developing siRNA transfection agents⁴⁶. When developing efficient fullerene nanomaterial transfection agents, certain conditions must be met. Firstly, the engineered fullerene nanomaterials should be able to form a stable complex with the desired sequence of siRNA, and that complex must deliver the RNA to the cytosol, thus protecting it from being degraded by nucleases⁴⁷. On the other hand, the complex that is formed between the RNA and cationic fullerene should not be too stable—the desired siRNA has to cleave from the complex and perform an endosomal escape and intracellular release to form the RNA-induced silencing complex (RISC)⁴⁸. The endosomal escape process and triggering the intracellular release tend to be the most important factors when developing effective siRNA delivery tools and are still not well understood for engineered nanomaterials⁴⁹. Here, we decided to test the ability of our fullerene nanomaterials to silence the GFP fluorescence signal using a prostate cancer cell line (DU145) due to the simplicity of the model²⁶. To better mimic in vivo conditions, we conducted all of the siRNA transfection experiments in the presence of FBS.

The R value (70) that used in the transfection experiments was calculated by dividing the nitrogen-to-phosphorus (N/P) ratio by two. Interestingly, due to the many positive charges placed at the nitrogen atoms in our two fullerene nanomaterials Hexakisamino_C₆₀ and JK39 (24 and 20, respectively), the R number was also high—the experimental values of the R parameter that were used for the siRNA transfection with the TPFE fullerene were between 20 and 50. Interestingly, in the transfection experiments carried out using the TPFE fullerene, it was dissolved in a potassium chloride solution (pH 2) to ensure the complete protonation of the aminofullerene




Figure 2. (A) Infrared spectrum of fullerene JK39; (B) ESI-mass spectrum of water-soluble fullerene JK39 (positive mode, 100 mV); (C) A high-resolution photoemission spectra of carbon and nitrogen measured in the fullerene nanomaterials JK39 and HexakisaminoC₆₀.

core before the formation of complex with desired siRNA. In our experiments two fullerene nanomaterials were dissolved in nuclease free water (pH 7) without adding any buffers—the low pH of that solution could have cytotoxic effects on the cells.

Our next step was the physicochemical characterization of the fullerene-siRNA complexes. Firstly, we studied the changes in the zeta potential of the formed complexes, assuming that it would decrease due to the anionic character of the RNA phosphate groups. As is depicted in Fig. 3C, the zeta potential of the HexakisaminoC₆₀-siRNA complex was +19.1 mV (a change from +28.6 mV), while the JK39-siRNA complex also had a higher zeta potential, measured at +32.7 mV—a change from +54 and +90 mV (Fig. 3D). Simultaneously, the HexakisaminoC₆₀-siRNA complex formed monodisperse aggregates (PDI=0.29) around 361 nm, whereas the JK39-siRNA complex had a polydisperse mixture of aggregates around 110, 604, and 4230 nm with PDI > 0.6. The observations mentioned above regarding the size of the siRNA complexes were further investigated with TEM morphology measurements, which revealed that was a fluffy-like structure (Fig. 3A) and polydispersity for the JK39-siRNA complex (Fig. 3B) and an image of the HexakisaminoC₆₀-siRNA complex which is presented in Fig. S8. The previously published reports by Nakamura et al. that described the TPFE-siRNA-plasma protein complex interactions revealed that it can disintegrate on a solid substrate, which suggests that it would also be unstable in vivo for releasing siRNA¹¹.





Figure 3. The TEM images of the siRNA-fullerene complexes that were measured for (A) HexakisaminoC₆₀ and (B) JK39 carbon nanomaterials; (C,D) zeta potentials of the siRNA-fullerene complexes that were measured for C-HexakisaminoC₆₀ and D-JK39 carbon nanomaterials.

Our final experiment was to test the siRNA transfection efficacy of the created highly water-soluble fullerene nanomaterials on prostate cancer cells that had been transfected with the EGFP-encoding plasmid and to compare their transfection properties in the presence of a serum with lipid-based Lipofectamine 3000 being used as a positive control. The results are depicted in Fig. 4, which shows a significant decrease in the fluorescence signal (to around 50%) when the cells were treated with the HexakisaminoC₆₀-siRNA complex. Notably, the fullerene nanomaterial JK39 had quite a low transfections efficacy. Based on the zeta potential measurements and TEM




Figure 4. The efficiency of the siRNA transfer in vitro with the engineered fullerene nanomaterials HexakisaminoC₆₀ and JK39 and the resulting EGFP silencing in a prostate cancer model (DU145 cells that had been transfected with the plasmid encoding EGFP). Each value represents the mean \pm SD (n = 3). Statistical significance was determined using the t-test (*p < 0.05; **p < 0.01; ***p < 0.001).

analysis, we suspect that JK39 forms an extremely stable complex with siRNA delivering it to the cytosol but that it cannot cleave it in cellular conditions. These effects could also be caused by the D-glucosamine moiety, which has an additional nitrogen connected at C2 position of glucosamine, which could be additionally protonated (as TFA salt) and that the differences in protein corona adsorbed on the surface of fullerene nanomaterials—JK39 possess additional sugar based hydroxyl groups. This explanation complies with the higher zeta potential of sugar-based JK39 complex and thus its higher stability within cells. Moreover siRNA, when used without adding of any transfection agent, works better; it decreases the GFP fluorescence signal to 75 percent of the starting signal, which further confirms our hypothesis. An attractive option for future biological studies of the JK39 fullerene nanomaterial could be to test the photocleavage of the JK39-siRNA stable complex based on the irradiation of cells with blue/green light (glycofullerenes are photosensitizers) and the generation of ROS, which led to good results for the C₆₀-Dex-NH₂ fullerene and the upconversion nanomaterials that were used as the siRNA transfection agents^{13,50}.

Conclusions

In summary, inspired by a previously developed TPFE cationic fullerene transfection agent, we developed two cationic fullerenes HexakisaminoC₆₀ and monoglucosamine JK39, which had a T_h symmetry that is characteristic for Bingel–Hirsch hexakisadducts. To the best of our knowledge, this is the first example of [60]fullerene hexakisadduct being ready to transfect siRNA. We postulate that the inactivity of JK39 fullerene in transfection experiments is caused by its high initial zeta potential and polydispersity. Future biological experiments should also determine how JK39 protects siRNA against enzymatic degradation, mainly by analyzing the adsorbed serum proteins (protein corona) on its surface. The cationic water-soluble fullerene nanomaterials to which adding interesting groups and tags (as sugars, azides or triple bonds for biorthogonal chemistry) can be attached, might hold considerable promise for in vivo siRNA delivery in the future.

Received: 7 March 2021; Accepted: 4 May 2021

Published online: 19 May 2021

References

1. Farjadian, F. *et al.* Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities. *Nanomedicine* **14**, 93–126. <https://doi.org/10.2217/nmm-2018-0120> (2019).
2. Mei, Y. *et al.* Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy. *Biomater. Sci.* **7**, 2640–2651 (2019).
3. Dammes, N. & Peer, D. Paving the road for RNA therapeutics. *Trends Pharmacol. Sci.* **41**, 755 (2020).

4. Dykxhoorn, D. M. & Lieberman, J. Running interference: Prospects and obstacles to using small interfering RNAs as small molecule drugs. *Annu. Rev. Biomed. Eng.* **8**, 377–402 (2006).
5. Garber, K. Alnylam launches era of RNAi drugs. *Nat Biotechnol.* **36**, 777–778 <https://doi.org/10.1038/nbt0918-777> (2018).
6. Kam, N. W. S., Liu, Z. & Dai, H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. *J. Am. Chem. Soc.* **127**, 12492–12493 (2005).
7. Nakamura, E. *et al.* Functionalized fullerene as an artificial vector for transfection. *Angew. Chem.* **112**, 4424–4427 (2000).
8. Sitharaman, B. *et al.* Water-soluble fullerene (C(60)) derivatives as nonviral gene-delivery vectors. *Mol. Pharm.* **5**, 567–578. <https://doi.org/10.1021/mp700106w> (2008).
9. Sigwalt, D. *et al.* Gene delivery with polycationic fullerene hexakis-adducts. *Chem. Commun.* **47**, 4640–4642 (2011).
10. Illescas, B. M. *et al.* Multivalent cationic dendrofullerenes for gene transfer: Synthesis and DNA complexation. *J. Mater. Chem. B* **8**, 4505–4515 (2020).
11. Minami, K. *et al.* siRNA delivery targeting to the lung via agglutination-induced accumulation and clearance of cationic tetraamino fullerene. *Sci. Rep.* **4**, 4916 (2014).
12. Minami, K., Okamoto, K., Harano, K., Noiri, E. & Nakamura, E. Hierarchical assembly of siRNA with tetraamino fullerene in physiological conditions for efficient internalization into cells and knockdown. *ACS Appl. Mater. Interfaces* **10**, 19347–19354 (2018).
13. Wang, J. *et al.* Visible light-switched cytosol release of siRNA by amphiphilic fullerene derivative to enhance RNAi efficacy in vitro and in vivo. *Acta Biomater.* **59**, 158–169 (2017).
14. Corbo, C. *et al.* The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. *Nanomedicine* **11**, 81–100 (2016).
15. Cai, X. *et al.* Characterization of carbon nanotube protein corona by using quantitative proteomics. *Nanomed. Nanotechnol. Biol. Med.* **9**, 583–593 (2013).
16. Belgorodsky, B. *et al.* Formation and characterization of stable human serum albumin–Tris-malonic Acid [C60] fullerene complex. *Bioconjug. Chem.* **16**, 1058–1062 (2005).
17. Calvaresi, M. & Zerbetto, F. Baiting proteins with C60. *ACS Nano* **4**, 2283–2299. <https://doi.org/10.1021/nn901809b> (2010).
18. Serda, M. *et al.* Glycofullerenes as non-receptor tyrosine kinase inhibitors-towards better nanotherapeutics for pancreatic cancer treatment. *Sci. Rep.* **10**, 1–11 (2020).
19. Gräfe, C. *et al.* Intentional formation of a protein corona on nanoparticles: serum concentration affects protein corona mass, surface charge, and nanoparticle–cell interaction. *Int. J. Biochem. Cell Biol.* **75**, 196–202 (2016).
20. Rudzinski, W. E., Palacios, A., Ahmed, A., Lane, M. A. & Aminabhavi, T. M. Targeted delivery of small interfering RNA to colon cancer cells using chitosan and PEGylated chitosan nanoparticles. *Carbohydr. Polym.* **147**, 323–332 (2016).
21. Hirsch, A., Lamparth, I., Grösser, T. & Karfunkel, H. R. Regiochemistry of multiple additions to the fullerene core: Synthesis of a Th-symmetric hexakis adduct of C60 with Bis (ethoxycarbonyl) methylene. *J. Am. Chem. Soc.* **116**, 9385–9386 (1994).
22. Campisciano, V., La Parola, V., Liotta, L. F., Giacalone, F. & Gruttadauria, M. Fullerene–Ionic-liquid conjugates: A new class of hybrid materials with unprecedented properties. *Chem. A Eur. J.* **21**, 3327–3334 (2015).
23. Serda, M. *et al.* Development of photoactive Sweet-C60 for pancreatic cancer stellate cell therapy. *Nanomedicine (Lond.)* **13**, 2981–2993. <https://doi.org/10.2217/nmm-2018-0239> (2018).
24. Serda, M. *et al.* Developing [60] fullerene nanomaterials for better photodynamic treatment of non-melanoma skin cancers. *ACS Biomater. Sci. Eng.* **6**, 5930 (2020).
25. Wang, T., Larcher, L. M., Ma, L. & Veedu, R. N. Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides. *Molecules* **23**, 2564 (2018).
26. Rak, M. *et al.* Boost of serum resistance and storage stability in cationic polypropenyl-based lipofection by helper lipids compositions. *Eur. J. Pharm. Biopharm.* **155**, 199–209 (2020).
27. Rak, M. *et al.* Efficient and non-toxic gene delivery by anionic lipoplexes based on polypropenyl ammonium salts and their effects on cell physiology. *J. Gene Med.* **18**, 331–342 (2016).
28. Chenon, B. & Sandorfy, C. Hydrogen bonding in the amine hydrohalides: I. General aspects. *Can. J. Chem.* **36**, 1181–1206 (1958).
29. Stewart, J. E. Vibrational spectra of primary and secondary aliphatic amines. *J. Chem. Phys.* **30**, 1259–1265 (1959).
30. Long, F. & Bakule, R. Keto-enol transformation of 1, 2-cyclohexanedione. II. Acid catalysis in strongly acidic media 1–3. *J. Am. Chem. Soc.* **85**, 2313–2318 (1963).
31. Perrin, C. L. Proton exchange in amides: Surprises from simple systems. *Acc. Chem. Res.* **22**, 268–275. <https://doi.org/10.1021/ar00164a002> (1989).
32. Cho, S. J. *et al.* N-protonation vs O-protonation in strained amides: Ab initio study. *J. Org. Chem.* **62**, 4068–4071. <https://doi.org/10.1021/jo962063z> (1997).
33. Cook, D. The infrared spectra of N-acyltrialkylammonium halides, in relation to those of amide salts. *Can. J. Chem.* **40**, 2362–2368 (1962).
34. Watts, J. F. High resolution XPS of organic polymers: The Scienta ESCA 300 database. G. Beamson and D. Briggs. 280pp., £ 65. John Wiley & Sons, Chichester, ISBN 0471 935921 (1992). *Surf. Interface Anal.* **20**, 267–267 (1993).
35. Yu, J. *et al.* Effects of fullerene derivatives on bioluminescence and application for protease detection. *Chem. Commun.* **48**, 11011–11013. <https://doi.org/10.1039/C2CC36099C> (2012).
36. Yan, X. *et al.* Preparation and characterization of electrochemically deposited carbon nitride films on silicon substrate. *J. Phys. D Appl. Phys.* **37**, 907 (2004).
37. Chi, K. *et al.* Freestanding graphene paper supported three-dimensional porous graphene–polyaniline nanocomposite synthesized by inkjet printing and in flexible all-solid-state supercapacitor. *ACS Appl. Mater. Interfaces* **6**, 16312–16319 (2014).
38. Veerapandian, M., Zhang, L., Krishnamoorthy, K. & Yun, K. Surface activation of graphene oxide nanosheets by ultraviolet irradiation for highly efficient anti-bacterials. *Nanotechnology* **24**, 395706 (2013).
39. Bon, S. B. *et al.* Plasma fluorination of chemically derived graphene sheets and subsequent modification with butylamine. *Chem. Mater.* **21**, 3433–3438 (2009).
40. Yu, B. *et al.* Functionalized graphene oxide/phosphoramidate oligomer hybrids flame retardant prepared via in situ polymerization for improving the fire safety of polypropylene. *RSC Adv.* **4**, 31782–31794 (2014).
41. Sadri, R. *et al.* A bio-based, facile approach for the preparation of covalently functionalized carbon nanotubes aqueous suspensions and their potential as heat transfer fluids. *J. Colloid Interface Sci.* **504**, 115–123 (2017).
42. Nishimura, O., Yabe, K. & Iwaki, M. X-ray photoelectron spectroscopy studies of high-dose nitrogen ion implanted-chromium: A possibility of a standard material for chemical state analysis. *J. Electron Spectrosc. Relat. Phenom.* **49**, 335–342 (1989).
43. Daems, N., Sheng, X., Vankelecom, I. F. & Pescarmona, P. P. Metal-free doped carbon materials as electrocatalysts for the oxygen reduction reaction. *J. Mater. Chem. A* **2**, 4085–4110 (2014).
44. Lapin, N. A. *et al.* Biotransport kinetics and intratumoral biodistribution of malonodiserinolamide-derivatized [60] fullerene in a murine model of breast adenocarcinoma. *Int. J. Nanomed.* **12**, 8289 (2017).
45. Deryabin, D. G. *et al.* A zeta potential value determines the aggregate's size of penta-substituted [60] fullerene derivatives in aqueous suspension whereas positive charge is required for toxicity against bacterial cells. *J. Nanobiotechnol.* **13**, 1–13 (2015).
46. Molinaro, R. *et al.* Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. *Expert Opin. Drug Deliv.* **10**, 1653–1668 (2013).
47. Sioud, M. On the delivery of small interfering RNAs into mammalian cells. *Expert Opin. Drug Deliv.* **2**, 639–651 (2005).

48. Wittrup, A. *et al.* Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. *Nat. Biotechnol.* **33**, 870–876 (2015).
49. Wang, J. *et al.* Far-red light-mediated programmable anti-cancer gene delivery in cooperation with photodynamic therapy. *Biomaterials* **171**, 72–82 (2018).
50. Zhang, Y. *et al.* Photo-tearable tape close-wrapped upconversion nanocapsules for near-infrared modulated efficient siRNA delivery and therapy. *Biomaterials* **163**, 55–66 (2018).

Acknowledgements

This work was supported by National Science Centre (Poland) Grant OPUS (UMO-2019/35/B/NZ7/02459) awarded to Dr. Maciej Serda. Dr. Mateusz Dulski acknowledges the financial support from the National Science Center based on decision 2017/26/D/ST8/01117. Additionally, we would like to thank Professor Ewa Swiezewska and Dr. Marek Masnyk of the Institute of Biochemistry and Biophysics Polish Academy of Sciences (PAS) in Warsaw for supplying PTAI-11. We would like also to thank Professor Ewa Zuba-Surma of the Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University for the possibility to use Guava® easyCyte 8 flow cytometer. We would also thank Mr Richard Visser from Advanced Chemistry Development UK Ltd (ACD/Labs) for his help in pK_a parameters calculation for selected malonic acid derivatives using the ACD Percepta Software.

Author contributions

Conception and design: M.S. and M.R. Acquisition of data: J.K., M.R., K.B., M.Z., O.G., M.D. and M.S. Analysis and interpretation of the data: M.R., K.B., M.Z., M.D., R.M., Z.M. and M.S. Manuscript preparation: M.S., M.R., M.D. and K.B. wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-89943-5>.

Correspondence and requests for materials should be addressed to M.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021, corrected publication 2022